[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"joint-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:joint-health":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100646099","a-clinical-trial-to-investigate-the-efficacy-and-safety-of-a-plant-derived-cetylated-fatty-acids-cfa-on-knee-pain-and-stiffness-in-healthy-adults-with-persistent-knee-pain-100646099",false,"NCT07695714","A Clinical Trial to Investigate the Efficacy and Safety of a Plant-based Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of a Plant-based Cetylated Fatty Acids on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain","Inclusion Criteria:\n\n1. Males \\& females between 35 and 75 years of age\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. A history of symptomatic knee discomfort, defined as experiencing pain in the target knee on most days of the month (≥ 15 days\u002Fmonth) for at least the past 3 months\n4. A KOOS Pain Subscale score ≥25 and ≤75\n5. Target knee is the primary source of lower-limb pain limiting walking and daily function, as confirmed by the QI\n6. A KOOS Function in daily living (ADL) score ≥25 and ≤ 80\n7. Travel less than 85% of predicted distance on the 6MWT as calculated using the Enright and Sherrill equation at screening (15)\n8. Agrees to refrain from taking any pain relievers during the study, except acetaminophen as a rescue medication specified by the study site\n9. Agrees to refrain from taking rescue medication for 48 hours prior to study visits\n10. Willingness and ability to complete questionnaires, functional tests, records, and diaries associated with the study and to complete all clinic visits\n11. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n12. Provided voluntary, written, informed consent to participate in the study\n13. Healthy as determined by medical history as assessed by the Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product, placebo, or rescue medication ingredients\n3. Individuals with a Body Mass Index (BMI) \\>34.9\n4. Prior clinician diagnosis (confirmed via x-ray) of knee OA or evidence of OA (e.g. severe deformity\u002Fconstant pain) or confounding pain condition such as fibromyalgia\n5. Intra-articular injection of corticosteroids or hyaluronic acid in either knee within 3 months prior to the Baseline visit\n6. Change in knee pain\u002Fstiffness\u002Fmobility treatment (e.g. physical therapy, braces, orthotics) in the past two months, as assessed by the QI\n7. Use of any assistive device for walking\u002Fmobility\n8. Any knee surgery within the past 6 months, or planned knee surgery within the study duration\n9. Individuals with muscle or skeletal disorders or other physical or gait disorders that limit mobility\u002Fwalking beyond what may be caused by the impacted knee, as assessed by the QI\n10. History of knee replacement\n11. Unstable metabolic disease or chronic diseases as assessed by the QI\n12. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n13. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n14. Type I or Type II and controlled Type II diabetes\n15. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n16. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n17. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n18. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n19. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n20. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n21. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n22. Use of prescription medical cannabinoid products\n23. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n24. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n25. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n26. Alcohol or drug abuse within the last 12 months\n27. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and safety of the investigational product\n28. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n29. Individuals who are unable to give informed consent\n30. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",true,"ALL","35 Years","75 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to investigate the efficacy and safety of plant-derived cetylated fatty acids (CFA) on joint health and mobility in adults with persistent knee pain. The main question it aims to answer is what is the change from baseline to day 42 in knee joint health, as assessed by the KOOS pain sub-scale scores, between plant-derived cetylated fatty acids (CFA) and placebo? Researchers will compare plant-derived cetylated fatty acids (CFA) with placebo to evaluate its effects on joint health, mobility, pain, and stiffness. Participants will be asked to:\n\n* Consume plant-derived cetylated fatty acids (CFA) or placebo daily from Day 1 until the day before the end-of-study visit\n* Have height, weight, heart rate, and blood pressure measurements taken\n* Complete the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire\n* Complete the 6-Minute Walk Test (6MWT)\n* Complete the 30 seconds chair sit to stand test\n* Complete the pain and stiffness Likert scale\n* Complete the subject treatment diary daily",[28,29,30],"Joint Health","Mobility","Knee Pain",[28,29,30,32,33],"Stiffness","Cetylated Fatty Acids","NOT_YET_RECRUITING","2026-08-14",{"date":37,"type":38},"2026-08-18","ACTUAL",{"date":40,"type":22},"2026-08",{"date":42,"type":22},"2027-02",{"name":44,"class":45},"Everwell Health","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100630866","a-decentralized-clinical-study-evaluating-the-effectiveness-of-two-different-doses-of-mycondro-on-physical-mobility-and-joint-health-100630866","NCT07493239","A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health","A Randomized, Double-blind Study Evaluating the Effectiveness of Two Different Doses of MyCondroTM on Physical Mobility and Joint Health Using Participant-Reported Outcomes in Individuals With Self-Reported Mobility Issues Associated With Knee Osteoarthritis","Inclusion Criteria:\n\n* Individuals age 45 years and older.\n* BMI range between 18-35 kg\u002Fm².\n* Self-reported mobility issues, including mobility impairment and joint discomfort associated with a known diagnosis of Knee Osteoarthritis. This impairment and discomfort must have persisted for at least 6 months prior to randomization and have been actively experienced within the last 3 months.\n* Willingness to avoid high Chondroitin Sulfate-containing foods (i.e., animal cartilages, bones, or derivatives such as gelatin) for the duration of the study period.\n* Willingness to refrain from supplements containing Chondroitin Sulfate for the duration of the study period.\n* Able to read and understand English.\n* Able to read, understand, and provide informed consent.\n* Able to use a personal smartphone device and download the Chloe by People Science app.\n* Able to receive shipments of the product at an address within the United States.\n* Able to complete study assessments over the course of up to 16 weeks.\n\nExclusion Criteria:\n\nAny potential participants will be excluded if they meet any of the following criteria:\n\n* Technology Limitation: Do not have a personal smartphone, lack internet access, or are unwilling to download the Chloe app.\n* Concomitant Therapies\n\n  1. Use of a Chondroitin Sulfate supplement in the 3 months prior to randomization.\n  2. Current use of other joint health supplements (e.g., glucosamine, hyaluronic acid, collagen peptides) for at least 4 weeks prior to randomization.\n  3. Use of any intra-articular or intravenous steroid injections in the last 3 months.\n  4. Receiving any investigational therapies or treatments within 30 days prior to randomization.\n\nOther Illnesses or Conditions\n\n1. Self-reported inflammatory arthropathies, such as Rheumatoid Arthritis, Gout, and Infectious Arthritis.\n2. Significant systemic lung, liver, heart, or kidney disease (excluding hypertension).\n3. Prior history of knee surgery within 3 months preceding the study period, or planned knee surgery (including arthroscopy) during the study period.\n4. Currently diagnosed with Alcohol Use Disorder and\u002For Substance Use Disorder.\n5. Currently pregnant, planning to become pregnant in the next 20 weeks, or breastfeeding.\n6. Presence of a knee prosthesis.\n7. Any significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes.\n\nAllergies and Intolerances\n\n1. Known hypersensitivity or previous allergic reaction to: Chondroitin sulfate, Maltodextrin, Mannitol, Magnesium Stearate, Silicon dioxide, Microcrystalline cellulose, or Talc.\n2. Known sensitivity or intolerance to wheat or gluten.\n\nGeneral Compliance\n\n1- Unlikely for any reason to be able to comply with the trial, or considered unsuited for participation in the study by the Principal Investigator.","45 Years",{"count":56,"type":22},240,[25],"This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.",[28],[61,62,63,64],"MyCondro, Gnosis, PS24","Joint function","Joint mobility","non-animal chondroitin sulfate","RECRUITING","2026-07-21",{"date":68,"type":38},"2026-07-22",{"date":70,"type":38},"2026-03-04",{"date":72,"type":22},"2026-11-02",{"name":74,"class":45},"Lesaffre International",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":82,"minAge":83,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100648847","a-clinical-trial-evaluating-the-influence-of-the-ingredients-mycondro-and-bovine-chondroitin-sulfate-on-the-behavior-of-cells-in-the-osteoarticular-sphere-100648847","NCT07727174","A Clinical Trial Evaluating the Influence of the Ingredients MyCondro™ and Bovine Chondroitin Sulfate on the Behavior of Cells in the Osteoarticular Sphere","Determination of the Biological Activity of Enriched Sera From Healthy Volunteers After Consumption of Chondroitin Sulfate of Both Animal and Fermentative Origin","Inclusion Criteria:\n\n* Men.\n* 18-35 years old (terminals included).\n* Liver test in the reference standards.\n* Renal assessment in the reference standards.\n* NFS in the reference standards.\n* CRP in the reference standards.\n* Blood pressure compatible with the conduct of the study.\n* Non-smoker or occasional smoker (\\\u003C5 cigarettes\u002Fday or \\\u003C 10ml per week of electronic cigarette liquid dosed at 3 mg\u002Fml of nicotine).\n* \\\u003C to 5 hours of intense sport per week.\n* Weight≥ to 60 kg.\n* BMI between 20 and 28 kg\u002Fm² (terminals not included).\n* Subjects able and willing to comply with the protocol and provide written informed consent.\n* Subjects affiliated to social security\n\nExclusion Criteria:\n\n* All types of vaccination under one month.\n* Alcohol consumption above WHO standards (\\>3 glasses of alcohol per day for men).\n* Ongoing treatment (medication, dietary supplement or probiotic) and within 4 weeks prior to inclusion.\n* Known pathology (including seasonal).\n* Allergy to the study product (all types)\n* People with a diet that is not suitable for the conduct of the study (e.g. vegetarian, vegan or vegan diet).\n* Change in eating habits in the 4 weeks prior to inclusion.\n* Medical and\u002For surgical history judged by the investigator or his\u002Fher representative to be incompatible with the trial.\n* Blood donation made in the 3 months prior to the inclusion visit or intending to do so during the study.\n* Persons under guardianship, curatorship, deprivation of liberty, safeguard of justice.\n* Refusal to sign the information sheet and consent.\n* Refusal to be registered on the National Register of Volunteers who lend themselves to research involving the human person.\n* Person who is excluded from another study on the national volunteer database, or who has received more than €6000 in the year following their participation in clinical studies.","MALE","18 Years",{"count":85,"type":22},10,[25],"The study evaluates the effect of chondroitin sulfate derived from fermentation (MyCondro™) and bovine chondroitin sulfate, on the health and function of the skeletal system ex vivo, including cartilage, joint capsule, and bone tissue. The primary aim of the study is to determine the influence of human sera enriched with metabolites resulting from the ingestion of the ingredients on the metabolism of human primary cells of cartilage (chondrocytes), joint capsule (synoviocytes) and bone tissue (osteoblasts). Furthermore, the absorption kinetics of MyCondro™ and Bovine CS will be described.",[28],[63,90,64,91],"Joint health","MyCondro™","2026-07-20",{"date":94,"type":38},"2026-07-27",{"date":96,"type":22},"2026-08-26",{"date":98,"type":22},"2027-05",{"name":74,"class":45}]